Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Atossa Therapeutics (NASDAQ: ATOS), a clinical-stage biopharmaceutical company focused on developing innovative breast cancer medicines, announced that CEO Dr. Steven Quay will present at the upcoming Jefferies Global Healthcare Conference. The presentation is scheduled for Thursday, June 5, 2025, at 7:35 a.m. Eastern Time. Investors can access the live webcast through the company's investor relations website, and the presentation will remain archived for 30 days. This conference provides Atossa an opportunity to showcase its developments in breast cancer therapeutics to the investment community.

News Market Reaction – ATOS

+11.54%

+11.54% Session move

In the trading session that priced this news, ATOS gained 11.54%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, June 2, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m. Eastern Time.

A live webcast of the presentation can be accessed on the Investors section of the Atossa website under "Events and Presentations" at https://investors.atossatherapeutics.com/news-events/events-presentations. The webcast will be archived for 30 days.

About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-302470615.html

SOURCE Atossa Therapeutics Inc

FAQ

When is Atossa Therapeutics (ATOS) presenting at the Jefferies Global Healthcare Conference 2025?

Atossa Therapeutics will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m. Eastern Time.

How can investors watch Atossa Therapeutics' (ATOS) presentation at the Jefferies conference?

Investors can watch the live webcast through the Investors section of Atossa's website under 'Events and Presentations' at investors.atossatherapeutics.com. The webcast will be archived for 30 days.

Who will be presenting for Atossa Therapeutics (ATOS) at the Jefferies Healthcare Conference?

Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa Therapeutics, will be presenting at the conference.

What is Atossa Therapeutics' (ATOS) main focus as a company?

Atossa Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing innovative medicines for breast cancer.